Breaks Categories: News

WednesdayMay 18, 2022 12:32 pm

BioMedNewsBreaks – Silo Pharma Inc. (SILO) CEO Featured in Bell2Bell Podcast Episode

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, and its founder and CEO Eric Weisblum are the center of attention in the most recent episode of the Bell2Bell Podcast. The Bell2Bell Podcast is designed to provide informative updates and exclusive interviews with executives operating in fast-moving industries. During the interview, hosted by Stuart Smith, Weisblum talks about his own background and experience in the industry as well as Silo Pharma’s business model and the company’s recent milestones. Weisman has been building and managing businesses for more than two decades and has…

Continue Reading

TuesdayMay 17, 2022 2:02 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in May 18 NYSE Trading Bell Ceremony

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the morning trading bell ceremony at the New York Stock Exchange on May 18, 2022. The first psychedelics company to be listed on the NYSE, Cybin started trading on the exchange in August 2021. In addition, Cybin announced that management team members will be hosting in-person meetings with institutional investors in New York City on May 18–19. “We are delighted to be part of this ceremony as we celebrate the innovation that Cybin is bringing to the challenges of mental health treatments…

Continue Reading

MondayMay 16, 2022 2:20 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2022 Financial, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released its first quarter 2022 financial report along with key updates on company strategies. The report pointed to recent approvals of a potentially pivotal Berubicin study in Europe that is expected to significantly drive patient enrollment and opportunities for Berubicin to be used in additional oncology indications with significant unmet needs and also noted that CNSP was granted fast track designation for Berubicin from the FDA, which provides more frequent interactions with the…

Continue Reading

FridayMay 13, 2022 12:02 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 Fiscal 2022 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced financial results for the third quarter ended March 31, 2022. “The third quarter of fiscal 2022 saw noticeable advancements across all of our programs, including commencing sales of the rare cannabinoids CBDV and CBT as raw ingredients for the health and wellness industry,” said Eric A. Adams, InMed president and CEO. “For the remainder of fiscal 2022, we will remain focused on driving our commercial operations by expanding our product portfolio, increasing sales of our existing and new rare…

Continue Reading

WednesdayMay 11, 2022 11:17 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright Global Investment Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the H.C. Wainwright Global Investment Hybrid Conference. The event is taking place May 23-26, 2022, at the Fontainebleau Miami Beach. Drysdale’s fireside chat will be webcast live at 12:30 p.m. ET on Wednesday, May 25. Interested parties should visit https://ibn.fm/0nlvQ to register and access the live webcast. An archived version of the webcast will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/hlEzH…

Continue Reading

WednesdayMay 11, 2022 11:10 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has closed the sale of non-core assets for $16.4 million. This news and additional information about the company was featured in an InvestmentPitch Media video, available for viewing on InvestmentPitch and YouTube or by visiting www.InvestmentPitch.com and entering “FSD Pharma” in the search box. Anthony Durkacz, interim CEO and co-executive chairman of FSD Pharma, said of the move: “This is a major accomplishment and puts us in a good position going forward especially considering the current state…

Continue Reading

TuesdayMay 10, 2022 2:09 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Closes CAD$16.4M Sale of Non-Core Assets

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the closing of the sale of the company’s former cannabis processing facility located in Cobourg, Ontario, Canada, for gross proceeds of CAD$16,400,000 in cash. “This is a major accomplishment and puts us in a good position going forward especially considering the current state of the capital markets. While most companies have taken huge write-downs on dispositions of cannabis-related assets, we were able to net significant profit from selling the facility,” said Anthony Durkacz, interim CEO…

Continue Reading

MondayMay 09, 2022 1:26 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from Phase I Clinical Trial for Novel Drug to Treat Concussion

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, has announced positive results from the first group of patients dosed with PRV-002 in its phase I clinical trial. According to the update, Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. Thus far, the drug has shown to be safe and well tolerated. “Based on our animal data and after reviewing our initial phase I trial safety reports, we are optimistic that PRV-002 will be a safe option for the treatment of concussion,” said Michael…

Continue Reading

ThursdayMay 05, 2022 3:01 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Demonstrating ‘Encouraging Promise in Treatment of GBM’

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical cancer drug developer, recently reported new advances in its rollout of a global clinical trial described as “potentially pivotal” in producing a treatment for an aggressive brain cancer, glioblastoma multiforme (“GBM”). On average, GBM is nearly 100% fatal just over a year into diagnosis. “CNS announced that France’s regulatory agencies have granted the company authority to pursue patient recruitment in the country…. France’s approval comes on the heels of similar authorization in Switzerland, where Swissmedic, the Swiss agency for therapeutic products, joined swissethics, the umbrella organization of the cantonal Ethics Committees (‘ECs’), in greenlighting…

Continue Reading

ThursdayMay 05, 2022 12:34 pm

BioMedNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Preclinical Study Findings to Be Showcased at Global Event Focused on Psychedelic-Assisted Therapy

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that an abstract highlighting preclinical data for its deuterated psilocybin analog CYB003 has been selected for a poster presentation at the “From Research to Reality” Global Summit on Psychedelic-Assisted Therapies and Medicines. The event is slated to take place from May 27-29, 2022, in Toronto, Canada. “It is an honor to participate in this inaugural conference devoted to psychedelic-assisted therapy and to be part of the rigorous scientific work being done in the field,” said Doug Drysdale, chief executive officer of Cybin. “The…

Continue Reading